Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

Published:2015-09-29 Issue:1 Volume:30 Page:48-56
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Pfirrmann M,Baccarani M,Saussele S,Guilhot J,Cervantes F,Ossenkoppele G,Hoffmann V S,Castagnetti F,Hasford J,Hehlmann R,Simonsson B

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2015261.pdf

Reference41 articles.

1. Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009; 114: 462 (abstr 1126).

2. Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014; 32: 415–423.

3. Castagnetti F, Gugliotta G, Breccia M, Specchia G, Intermesoli T, Capucci A et al. Frontline treatment with imatinib mesylate in chronic myeloid leukemia patients in early chronic phase: a very long-term analysis by the GIMEMA CML Working Party. Blood 2013; 122: 258 (abstr 258).

4. Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 686–692.

5. Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia 2013; 27: 2016–2022.

Cited by 229 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia;New England Journal of Medicine;2024-09-12

2. Therapeutic Leukapheresis in a Pediatric Acute Myeloid Leukemia (AML) Crisis as a Critical Life-Saving Adjunctive Therapy: A Case Report;Cureus;2024-08-26

3. Enhanced venetoclax delivery using L-phenylalanine nanocarriers in acute myeloid leukemia treatment;Chinese Chemical Letters;2024-08

4. Chronic Myeloid Leukemia in Adolescents and Young Adults: Clinicopathological Variables and Outcomes;Oncology;2024-07-16

5. Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial;Leukemia;2024-07-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3